158 related articles for article (PubMed ID: 37099942)
21. Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers.
Lilong Z; Kuang T; Li M; Li X; Hu P; Deng W; Wang W
Clin Nutr; 2024 Jan; 43(1):31-41. PubMed ID: 38000193
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy.
Kuang T; Zhang L; Qiu Z; Zhang Y; Wang W
Front Immunol; 2023; 14():1261202. PubMed ID: 38077332
[TBL] [Abstract][Full Text] [Related]
23. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
24. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
[TBL] [Abstract][Full Text] [Related]
25. Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors.
Zhang L; Ma W; Qiu Z; Kuang T; Wang K; Hu B; Wang W
Front Immunol; 2023; 14():1219929. PubMed ID: 37545502
[TBL] [Abstract][Full Text] [Related]
26. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
27. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
Wu Q; Liu J; Wu S; Xie X
Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.
Wang BC; Zhang ZJ; Fu C; Wang C
Medicine (Baltimore); 2019 Nov; 98(47):e18054. PubMed ID: 31764833
[TBL] [Abstract][Full Text] [Related]
29. The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Ke L; Li S; Huang D
Int Immunopharmacol; 2023 Nov; 124(Pt B):110986. PubMed ID: 37748223
[TBL] [Abstract][Full Text] [Related]
30. Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy.
Zhang L; Chen C; Chai D; Li C; Kuang T; Liu L; Dong K; Deng W; Wang W
Front Pharmacol; 2022; 13():1018411. PubMed ID: 36225582
[No Abstract] [Full Text] [Related]
31. The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials.
Dubois M; Liscia N; Brunetti O; Ziranu P; Lai E; Argentiero A; Mazza E; Cascinu S; Silvestris N; Casadei-Gardini A; Scartozzi M
Crit Rev Oncol Hematol; 2022 May; 173():103674. PubMed ID: 35364261
[TBL] [Abstract][Full Text] [Related]
32. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
Xu H; Cao D; Zheng Y; Zhou D; Chen X; Lei J; Ge W; Xu X
Int Immunopharmacol; 2021 Nov; 100():108135. PubMed ID: 34530205
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
[TBL] [Abstract][Full Text] [Related]
34. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
[TBL] [Abstract][Full Text] [Related]
35. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
Zhang J; Wang L; Zhang S; Cao R; Zhao Y; Zhao Y; Song Y; Guo Z
BMC Cancer; 2024 Feb; 24(1):266. PubMed ID: 38408930
[TBL] [Abstract][Full Text] [Related]
36. Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Mao Z; Jia X; Jiang P; Wang Q; Zhang Y; Li Y; Fu X; Jiao M; Jiang L; Liu Z; Guo H
Front Immunol; 2022; 13():861723. PubMed ID: 35603146
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
Wang R; Lin N; Mao B; Wu Q
J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
39. A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors.
Crespin A; Le Bescop C; de Gunzburg J; Vitry F; Zalcman G; Cervesi J; Bandinelli PA
Front Oncol; 2023; 13():1075593. PubMed ID: 36937417
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer/Esophagogastric Junction Cancer: A Systematic Review and Meta-Analysis.
Wu F; Hong J; Du N; Wang Y; Chen J; He Y; Chen P
Anticancer Agents Med Chem; 2022; 22(1):143-151. PubMed ID: 33719964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
